人骨髓纤维化干祖细胞在MISTRG小鼠中植入增强
为改善骨髓增殖性肿瘤在免疫缺陷小鼠中植入率低的问题,研究者将人细胞因子生理性表达与人信号调节蛋白α表达结合于Rag2-/-Il2rγ-/-(MISTRG)小鼠,评估原发、真性红细胞增多症后或原发性血小板增多症后骨髓纤维化(MF)患者干祖细胞(HSPC)的植入。MISTRG小鼠支持所有受试患者样本的植入,不依赖MF疾病分期或危险分层,且骨髓、外周血和脾脏中人MF植入水平显著高于标准免疫缺陷小鼠,并支持二次再植入。
要点
- MISTRG小鼠支持所有受试MF患者样本的植入,不依赖疾病分期或危险分层。
- MISTRG小鼠骨髓、外周血和脾脏中人MF植入水平显著高于标准免疫缺陷小鼠,并支持二次再植入。
- 14例受试患者样本中仅3例在MISTRG小鼠中发生骨髓纤维化。
核心结论
- 所建立的MF患者来源异种移植模型支持MF HSPC的稳健植入并维持患者中观察到的遗传复杂性,适用于进一步测试新型治疗药物以加速其进入临床试验。
研究设计与样本
- 将人细胞因子(巨噬细胞集落刺激因子、白细胞介素-3、粒细胞-巨噬细胞集落刺激因子和血小板生成素)生理性表达与人信号调节蛋白α表达结合于Rag2-/-Il2rγ-/-(MISTRG)小鼠,并与标准免疫缺陷NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ和Rag2-/-Il2rγ-/-小鼠对比,评估原发、真性红细胞增多症后或原发性血小板增多症后MF患者HSPC的植入。
主要发现
- MISTRG小鼠支持所有受试患者样本的植入,不依赖MF疾病分期或危险分层。
- MISTRG小鼠骨髓、外周血和脾脏中人MF植入水平显著高于标准免疫缺陷小鼠,并支持二次再植入。
- 14例受试患者样本中仅3例在MISTRG小鼠中发生骨髓纤维化。
- 所有异种移植物中均鉴定出疾病驱动突变,靶向测序显示8例中7例维持原发患者样本的克隆组成。
- 用当前标准治疗Janus激酶抑制剂芦可替尼治疗植入小鼠导致人嵌合率降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The engraftment potential of myeloproliferative neoplasms in immunodeficient mice is low. We hypothesized that the physiological expression of human cytokines (macrophage colony-stimulating factor, interleukin-3, granulocyte-macrophage colony-stimulating factor, and thrombopoietin) combined with human signal regulatory protein α expression in Rag2-/-Il2rγ-/- (MISTRG) mice might provide a supportive microenvironment for the development and maintenance of hematopoietic stem and progenitor cells (HSPC) from patients with primary, post-polycythemia or post-essential thrombocythemia myelofibrosis (MF). We show that MISTRG mice, in contrast to standard immunodeficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ and Rag2-/-Il2rγ-/- mice, supported engraftment of all patient samples investigated independent of MF disease stage or risk category. Moreover, MISTRG mice exhibited significantly higher human MF engraftment levels in the bone marrow, peripheral blood, and spleen and supported secondary repopulation. Bone marrow fibrosis development was limited to 3 of 14 patient samples investigated in MISTRG mice. Disease-driving mutations were identified in all xenografts, and targeted sequencing revealed maintenance of the primary patient sample clonal composition in 7 of 8 cases. Treatment of engrafted mice with the current standard-of-care Janus kinase inhibitor ruxolitinib led to a reduction in human chimerism. In conclusion, the established MF patient-derived xenograft model supports robust engraftment of MF HSPCs and maintains the genetic complexity observed in patients. The model is suited for further testing of novel therapeutic agents to expedite their transition into clinical trials.
引用
- Lysenko V, Wildner-Verhey van Wijk N, Zimmermann K, et al. Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. Blood Adv. 2020. PMID: 32502268. doi:10.1182/bloodadvances.2019001364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。